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ABSTRACT
Introduction: Chronic illnesses are marked by
ﬂuctuations and variations over time. Individuals with
chronic illness experience pain and other symptoms
that are not always adequately managed. Their
caregivers often have to deal with enormous burden
as the illness progresses. Palliative care can serve as
an intervention to manage chronic illness, not just at
the end of life but also in the early phases of illness.
Methods and analysis: Randomised and non-
randomised studies will be included in the systematic
review. The focus will be on non-cancer chronic
illness. Sources of data will be from PubMed and other
databases and will include the reference list of studies
included in the systematic review. The primary
outcome will be to assess the efﬁcacy of palliative care
on chronic illness. Secondary outcomes will include
health-related quality of life, care giver burden, quality
of care and cost-effectiveness of interventions. The
study population will consist of patients aged 18 years
or over.
Ethics and dissemination: For purposes of privacy
and conﬁdentiality, the systematic review will be
limited to studies with de-identiﬁed data. The
systematic review will be published in a peer-reviewed
journal. It will also be disseminated electronically and
in print. Brief reports of review ﬁndings will be
disseminated directly to appropriate audiences via
email and other modes of communication. Updates of
the review will be conducted to inform and guide
healthcare practice and policy.
Trial registration
number: PROSPEROCRD42011001794.
INTRODUCTION
The World Health Organization (WHO)
deﬁnes palliative care as an intervention that
improves the quality of life of patients and
their families experiencing intermittent
illness, with the ultimate goal being to offer
pain and symptom relief, as well as spiritual
and psychosocial support.
1 Chronic illnesses
are characterised by ﬂuctuations in trajectory,
uncertainty in prognoses, extended disease
timelines and stress. The Centers for Disease
Control states that chronic diseasesdsuch as
heart disease, stroke, cancer, diabetes and
arthritisdare among the most common,
costly and preventable of all health prob-
lems.
2 Chronic diseases are also the leading
causes of disability and death in the USA.
2
Murray et al posit that health, social and
palliative care services are continuing to fail
many people with progressive chronic
illnesses in whom death may be approaching,
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ARTICLE SUMMARY
Article focus
- Will a systematic review of palliative care for the
management of chronic illness reveal any
palliative care disparities between non-cancer
patients and cancer patients?
- Does palliative care lead to symptom improve-
ment and pain control in chronically ill patients?
- How does palliative care impact health-related
quality of life?
Key messages
- A primary focus of the study is on non-cancer
chronic illness.
- Study examines eight different domains of
palliative care.
- Does palliative care lead to better or worse
outcomes in chronic illness?
Strengths and limitations of this study
- This study concerns palliative care for the
management of chronic illness. To our knowl-
edge, this is the ﬁrst protocol of a systematic
review that will attempt to assess the eight
different domains of palliative care.
- We will be including observational studies in
the systematic review because we believe that
observational studies will provide us with valid
and useful information (that might be lacking in
randomized studies) to address key messages
of this study.
- The risk for bias might be heightened by the
inclusion of non-randomized studies; however,
we have made it clear that we will give priority
to high-quality evidence, where it exists, and will
interpret results that are highly prone to bias with
great caution.
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Open Access Protocolreﬂecting a failure to think proactively and holistically
about their care.
3 In the absence of adequate interven-
tions aimed at caring for patients with chronic illness,
the quality of life and symptom burden faced by such
patients are bound to be subpar and excessive.
4 It is
important to mention that while the terms chronic
illness and chronic disease are used interchangeably,
they convey slightly different meanings. Chronic disease
is deﬁned on the basis of the biomedical disease classi-
ﬁcation,
5 for example, asthma, sickle cell, depression
and diabetes. Chronic illness is the personal experience
of living with the afﬂiction that accompanies chronic
disease. Chronic illness is often not recognised in health
systems because it does not ﬁt into a biomedical or
administrative classiﬁcation.
6
In order to alleviate the debilitating symptoms and
enhance the quality of life of chronically ill patients,
palliative care serves as an effective tool for pain relief,
symptom improvement and existential well-being.
Furthermore, several studies have shown that patients
with non-cancer chronic illness have signiﬁcantly
impaired quality of life and emotional well-being that
may often not be as well met as those of patients with
cancer nor do they receive holistic care that is appro-
priate to their needs.
7e9 Unrelieved pain is more than
a symptom and has a pathophysiology that, if left
unchecked, can ultimately become a disease itself.
9
While the focus of palliative care has been end of life,
we suggest that the palliative care model be used for
patients with chronic illness, not just at the end of life
but in the early phases of illness.
Several systematic reviews have been conducted on
palliative care, but they have focused strictly on end-of-life
issues or in some cases have failed to adequately address
symptom prevalence in chronically ill patients or to assess
quality of care or all domains of palliative care.
10e12
This protocol is for a systematic review that will attempt
to assess the eight different domains of palliative care, as
laid out by The National Consensus Project (NCP) for
Quality Palliative Care in the USA and which also cover
the WHO deﬁnition of palliative care.
13 These domains
are structure and process of care; physical aspects of
care; psychological and psychiatric aspects of care; social
aspects of care; spiritual, religious and existential aspects
of care; cultural aspects of care; care of the imminently
dying patient and ethical and legal aspects of care.
The primary objective of this systematic review will be to
assess the efﬁcacy of integrated and standard palliative
care on symptom improvement (eg, dyspnoea relief).
In addition, secondary outcome such as health-related
quality of life and care giver burden will be assessed. The
cost-effectiveness of palliative care interventions in the
management of chronic illness will be examined.
Methods and analysis
For the systematic review, we will not be limiting the
studies selected to randomised controlled trials. Data
from randomised controlled trials are often insufﬁcient
to address all aspects of palliative care practice, and
randomised controlled trials on palliative care are
sometimes unethical or difﬁcult to conduct.
14 Further,
Norris et al
15 state that the default strategy in systematic
reviews should be to consider including observational
studies and the decision rests on the answer to two
questions: (1) are there gaps in the trial evidence for the
review questions under consideration? And (2) will
observational studies provide valid and useful informa-
tion to address key questions?
16 17
In view of the above, we have decided a priori to
develop a protocol that does not rule out the use of
observational studies to assess the effectiveness and
limitations of palliative care interventions on chronic
illness. In doing so, we are cognizant of the fact that
non-randomised studies as well as non-double blind
studies are prone to bias. Therefore, we will give the
utmost priority to high-quality evidence, when and
where it exists, and will interpret with maximum caution,
bias-prone studies and study designs.
In designing the study, the following questions and
objectives will take precedence:
< Will a systematic review of palliative care for chron-
ically ill patients reveal disparities in palliative care
between non-cancer and cancer patients?
< Will such a systematic review also reveal the efﬁcacy
of palliative care in chronic illness symptom improve-
ment?
< To assess the efﬁcacy of palliative care on health-
related quality of life.
< Identify the efﬁcacy of palliative care on patient, care
giver and provider satisfaction.
< What is the cost-effectiveness of palliative care for
non-cancer chronic illness?
< To answer these questions, a literature search of the
following databases will be conducted:
< MEDLINE
< EMBASE
< The Cochrane Central Register of Controlled Trials
(CENTRAL)
< Cochrane Database of Systematic Reviews (CDSR)
< Database of Abstracts of Reviews of Effects (DARE)
< PubMed
< Health Economic Evaluations Database (HEED)
< The Latin American and Caribbean Literature on
Health Sciences Database (LILACS)
< African Index Medicus
< In order to minimise bias, we will also conduct a search
of pertinent grey literature.
< Two search strategies for MEDLINE are available in
appendices 1 and 2 of this protocol.
Inclusion criteria
Primary studies involving patients with non-cancer
chronic illness: randomised controlled trials, quasi-
randomised controlled trials, observational studies
and large registry studies that address chronic illness and
palliative care. Study population with a mean age of 18
years or older (or identiﬁed subgroup of people
>18 years); articles written in English; articles published
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grey literature; articles focusing mainly on palliative care
and its domains including assessment and management
of physical, psychological and spiritual symptoms,
quality of care, quality of life and advance care plan-
ning; studies that were a minimum of 12-week duration
with at least 10 participants per group.
Exclusion criteria
Studies focusing strictly on individual components of
palliative care, such as advance care planning or care
giver burden, studies focused solely on cancer patients
admitted or referred to palliative care, studies focused
on patients under 18 years of age, studies with a high risk
of bias (based on a predeﬁned threshold) and studies
of <12 weeks duration with <10 participants per group.
Studies published before 2000 will also be excluded
because palliative care was recognised as a specialty and
service in 2000.
18 Furthermore, palliative care practice
has changed signiﬁcantly since 2000;
18 however, we will
reference systematic reviews that addressed the pre-2000
literature, including key intervention studies included in
those reviews.
18
Studies will be characterised by intervention, outcomes
measured, study population, settings and quality of
research design.
Types of interventions
Interventions will be classiﬁed based on whether they
incorporate standard or integrative palliative care or
whether they incorporate usual care. Such interventions
must address more than one of the eight domains of
palliative care that are relevant to this study. If necessary,
interventions that do not satisfy this taxonomy will be
given a post hoc classiﬁcation.
Types of outcome measures
Primary outcomes
< Efﬁcacy of integrated palliative care on symptom
improvement (eg, pain relief).
< Efﬁcacy of standard palliative care on symptom
improvement (eg, pain relief).
Secondary outcomes
< Health-related quality of life (of patient).
< Quality of care (eg, structure and process of care;
physical aspects of care; psychological and psychiatric
aspects of care; spiritual, religious and existential aspects
of care; cultural aspects of care; care of the imminently
dying patient or ethical and legal aspects of care).
< Care giver burden (eg, physical or psychological
distress).
< Cost-effectiveness of interventions: we suggest that
the rendition of effective and timely palliative care
will provide the following economic beneﬁts:
1. Individual medical cost reduction including costs
of hospitalisation, drugs, feeding expenses and
opportunity cost of long hospital inpatient
accommodation.
2. Effective control and management of professional
time that could be translated into lower operational
cost including overtime payment to service
attendants.
3. Decreasing social cost of medical and professional
service delivery.
4. Reduced aggregate cost of funeral expenses.
5. Effective prediction or estimation of budgets for non-
oncologic and cancer patients healthcare delivery.
6. Alleviation of burden of excessive and extended
charges of patient’s medical expenses to insurance
companies.
7. Reduced social security expenses by the governments
emanating from lower claims of health beneﬁts by
patients.
8. Longer life span for chronically ill patients, who might
subsequently contribute positively to the community
in other social service areas.
Therefore, in attempting to evaluate the cost-effectiveness
of palliative care interventions used in the management
of chronic illness, we will take into account how included
studies address the effects of palliative care on these
beneﬁts and the ﬁnal outcomes that were obtained at the
conclusion of these studies.
All primary and secondary outcomes measured in the
systematic review will be assessed using a validated or
substantiated scale or tool, for example: Care giver
Burden Scale, McGill Pain Questionnaire, Palliative
Outcomes Scale and EQ-5D. Cost-effectiveness studies
will be appraised for quality based on a grading scheme
that will encompass deﬁnition and presentation of the
problem, measurement and data and analytic method-
ology.
19 In the process of assessing the cost-effectiveness,
we will highlight the potential opportunity costs involved
because recommendations that ignore opportunity costs
will either not be relevant to decision makers or, if
blindly followed, may result in inappropriate adoptions
or rejections of treatments.
20
The overall aim of the systematic review will be to
provide a summary of the data available in the studies
included and perhaps suggestions for practice, policy
and research.
Data extraction (selection and coding)
Standardised data extraction forms will be created for
the study. Two researchers will independently perform
the data extraction. One researcher will extract the
data with the second researcher independently checking
the data extraction forms for accuracy and detail. If
disagreements occur between assessors, they will be
resolved according to a predetermined strategy using
consensus and arbitration, as necessary. Relevant missing
data will be sought by contacting original authors of
included studies. Similarly, we will deal with missing
data for patients not completing a study, by imputing
the missing data and accounting for the fact that they
were imputed with uncertainty. In speciﬁc, we will use
multiple imputation methods to handle missing data.
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Risk of bias (quality) assessment
The Cochrane Collaboration’s tool for assessment of
risk of bias will be used. A risk of bias table will be
generated with the following entries: adequate sequence
generation, allocation concealment, blinding, incomplete
outcome data addressed, free of selective reporting, and
free of other bias. Only studies meeting speciﬁc criteria
will be included in the primary analysis. The threshold
for study selection adopted in this protocol will be used
in the systematic review. Data from unpublished studies
will be analysed and included (if appropriate) with the
aim of reducing bias. For non-randomised studies, focus
on speciﬁc aspects of the studies (eg, outcome assess-
ment) and the extent to which they are susceptible to bias
also be used to assess risk of bias. Notably, either the Risk
of Bias Assessment tool for Non-Randomised Studies
(RoBANS) developed by The Cochrane Collaboration as
a component of The Cochrane Collaboration’s tool
for assessing risk of bias in randomised trials
22 or the
Newcastle-Ottawa Scale will be used to assess risks of
bias in non-randomised studies.
23
RoBANS is available in Review Manager (RevMAN).
In using RoBANS, certain items in the Risk of Bias table
will be changed, for example, adequate sequence gener-
ation will be changed to allocation concealment (in order
to minimise allocation and selection bias)
24 and selection
of participants will be changed to confounding variables.
List of potential confounding factors
< Demographic characteristics
25
< Prognostic factors
< Severity of illness
< Symptom burden
< Comorbidities
< Functional status
< Social support
< Financial resources
< Factors existent at baseline
< Individual preferences towards avoidance of high-cost
settings
< Values and preferences for quality of life and life-
sustaining treatments
< Clinician practice characteristics
< Urban/rural location of institution
< Type of institution
< Values and preferences towards treatment options
and goals of care
< Team/family dynamics
Methods to control potential confounding factors
Multivariable regression modelling or propensity scores
will be used to control for potential confounding factors.
25
Methods to assess the susceptibility of primary studies to
confounding
We will attempt to select the best set of confounding
variables that include the most relevant factors likely
to account for differences between intervention and
comparison groups and provide a balance in the trade-
off between bias and variance to obtain more precise
estimates of the treatment effects.
25 26
Evaluating uncertainty
We will evaluate uncertainty through sensitivity analysis
and statistical tests comparing effects, costs or cost-
effectiveness.
26
Strategy for data synthesis
Due to the diversity of included studies, a narrative
approach will be used for synthesis. Quantitative synthesis
of results will be considered in the presence of several
high-quality studies of similar design. Sources of hetero-
geneity will be investigated using the I
2 statistic.
22
Ethics and dissemination
For purposes of privacy and conﬁdentiality, the systematic
review will be limited to studies with de-identiﬁed data.
The systematic review will be published in a peer-
reviewed journal. It will also be disseminated electroni-
cally and in print. Brief reports of review ﬁndings will be
disseminated directly to appropriate audiences via email
and other modes of communication. Updates of the
review will be conducted to inform and guide healthcare
practice and policy.
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APPENDIX 1
Medline search strategy
1. Palliative Care/
2. pallia$.tw.
3. or 1 2
4. Advance Care Planning/
5. (advance care planning).tw.
6. or 4-5
7. or 3,6
8. Chronic Disease/
9. (chronic disease).tw.
10. Arthritis/
11. arthritis.tw.
12. Asthma/
13. asthma.tw.
14. Anemia, Sickle Cell/
15. sickle cell.tw.
16. HIV Infections/
17. HIV.tw.
18. AIDS.tw.
19. Depressive Disorder/
20. depression.tw.
21. Diabetes Mellitus/
22. diabetes.tw.
23. Pulmonary Disease/Chronic Obstructive/
24. emphysema.tw.
25. (chronic bronchitis).tw.
26. Heart Diseases/
27. cardiac.tw.
28. (congestive heart failure).tw.
29. CHF.tw.
30. Hypertension/
31. Affective Disorders/Psychotic
32. bipolar.tw.
33. manic.tw.
34. Stroke/
35. stroke.tw.
36. or 8-35
37. and 7, 36
38. (symptom improvement).tw.
39. symptom.tw.
40. Quality of Life/
41. (quality of life).tw.
42. Quality of Health Care/
43. quality.tw.
44. Cost of Illness/
45. Caregivers/
46. (caregiver burden).tw.
47. or 38e 46
48. and 37, 47
49. Young Adult/
50. adult.tw.
51. Adult/
52. Middle Aged/
53. Aged/
54. Aged, 80 and over
55. or 47-52
56. and 48, 55
Facets per patron:
Palliative Care or Advance Care Planning
And
Chronic Disease or (Eleven conditions speciﬁcally named: Arthritis or
Asthma or Sickle Cell or HIV/AIDS or Depression or Diabetes or
Emphysema or Chronic Obstructive Pulmonary Disease or Heart
Disease or High Blood Pressure or a mood disorder other than
depression or Stroke)
And
(Symptom improvement) or (Quality of Life) or (Cost of Illness) or
(caregiver burden)
And
Adults over age 18
APPENDIX 2
1. Palliative Care/
2. pallia$.tw.
3. or 1 2
4. Advance Care Planning/
5. (advance care planning).tw.
6. or 4-5
7. or 3,6
8. Chronic Disease/
9. (chronic disease).tw.
10. Arthritis/
11. arthritis.tw.
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13. asthma.tw.
14. Anemia, Sickle Cell/
15. sickle cell.tw.
16. HIV Infections/
17. HIV.tw.
18. AIDS.tw.
19. Depressive Disorder/
20. depression.tw.
21. Diabetes Mellitus/
22. diabetes.tw.
23. Pulmonary Disease/Chronic Obstructive/
24. emphysema.tw.
25. (chronic bronchitis).tw.
26. Heart Diseases/
27. cardiac.tw.
28. (congestive heart failure).tw.
29. CHF.tw.
30. Hypertension/
31. Affective Disorders/Psychotic
32. bipolar.tw.
33. manic.tw.
34. Stroke/
35. stroke.tw.
36. or 8-35
37. and 7, 36
38. (symptom improvement).tw.
39. symptom.tw.
40. Pain/
41. (pain).tw.
42. Dyspnea/
43. dyspnea.tw.
44. Fatigue/
45. fatigue.tw.
46. Constipation/
47. constipation.tw.
48. Nausea/
49. nausea.tw.
50. Sleep Initiation and Maintenance Disorders/
51. insomnia.tw.
52. Quality of Life/
53. (quality of life).tw.
54. Quality of Health Care/
55. quality.tw.
56. Cost of Illness/
57. Caregivers/
58. (caregiver burden).tw.
59. or 38 - 58
60. and 37, 59
61. Young Adult/
62. adult.tw.
63. Adult/
64. Middle Aged/
65. Aged/
66. Aged, 80 and over
67. or 61-66
68. and 60, 67
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